Apr 08, 2019 8:15am EDT SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
Apr 03, 2019 8:30am EDT SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
Mar 14, 2019 4:39pm EDT SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Mar 07, 2019 9:34am EST SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note
Feb 28, 2019 8:30am EST SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Jan 30, 2019 4:05pm EST SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Jan 22, 2019 8:45am EST SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
